Decoy Therapeutics Inc. IPO Filing Research

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

First tracked pre-IPO filing for this issuer.

2026-06-24 · 9999999995-26-002113

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Price $6.25 · 808,000 shares · Gross proceeds $5,000,000

Common Stock, par value $0.0001 per share · Exchange Nasdaq · Ticker DCOY · Use of proceeds Proceeds from the sale of Purchase Shares will be used to redeem Series B Preferred Stock and for working capital · Underwriters C/M Capital Master Fund, LP

2026-06-15 · 0001193125-26-269891

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

First tracked pre-IPO filing for this issuer.

2026-06-05 · 0001193125-26-259729

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows FWP and confirms the priced prospectus.

Price $1.50 · 2,514,335 shares · Gross proceeds $6,999,784

Series A Warrant to purchase one share · Exchange NASDAQ · Ticker SLRX · Over-allotment 699,999 · Series A Warrants (5-year expiration) and Series B Warrants (1-year expiration) accompany common stock offerings · Underwriters Ladenburg Thalmann

2025-11-12 · 0001628280-25-051365

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

Exchange NASDAQ

2025-11-10 · 0001615219-25-000157

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $4.08 · 1,960,784 shares

Series A Warrant to purchase one share · Exchange NASDAQ · Series A Warrants (5-year expiration), Series B Warrants (1-year expiration), and pre-funded warrants with $0.0001 exercise price · Use of proceeds To fund the merger and related transactions

2025-10-21 · 0001628280-25-045619

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

Exchange NASDAQ · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2025-09-26 · 0001615219-25-000137

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B5 filing.

Price $5.27 · 1,518,027 shares

Common · Exchange NASDAQ · Series A Warrants (5-year expiry), Series B Warrants (1-year expiry), Pre-Funded Warrants (exercise price $0.0001), Representative Warrants · Use of proceeds Proceeds will be used for the merger and general corporate purposes

2025-09-23 · 0001628280-25-042500

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

Gross proceeds $2,600,000

Common Stock · Exchange Nasdaq · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2025-08-22 · 0001628280-25-041046

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $0.74 · 10,794,765 shares

Common Stock · Exchange NASDAQ · Series A Warrants, Series B Warrants, Pre-Funded Warrants, and Representative Warrants · Flags warrants

2025-08-08 · 0001628280-25-039090

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

shares in the combined company · Exchange NASDAQ · Ticker SLRX · Use of proceeds to fund the merger and meet NASDAQ listing requirements

2025-08-05 · 0001615219-25-000082

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.74 · 10,794,765 shares

Common Stock · Exchange Nasdaq Capital Market · Common Stock and accompanying common warrants · Series A Warrants (5-year term) and Series B Warrants (6-month term) with exercise price resets and zero-cash exercise features · Use of proceeds Working capital · Flags warrants

2025-07-31 · 0001628280-25-036892

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Common Stock · Exchange NMS · Ticker SALR · Pre-Funded Warrants to Purchase Common Stock and Representative Warrants · Use of proceeds Proceeds to be used for general corporate purposes · Flags warrants

2025-06-16 · 0001628280-25-031631

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Class A · Pre-funded warrants and representative warrants to purchase common stock · Use of proceeds General corporate purposes

2025-05-22 · 0001628280-25-027131

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B5 filing.

Common Stock · Pre-funded warrants to purchase common stock with $0.0001 exercise price, exercisable for one share each

2025-04-17 · 0001628280-25-018065

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows S-1 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq · Ticker SLRX · Use of proceeds Proceeds to be used for general corporate purposes · Underwriters Ladenburg Thalmann & Co. Inc.

2025-03-11 · 0001615219-25-000029

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

2025-01-21 · 0001628280-25-001947

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

6,733,334 shares

Common Stock, $0.0001 par value · Exchange Nasdaq · Ticker SLRX · Selling stockholders only · Use of proceeds no issuer proceeds · Underwriters C/M Capital Master Fund, LP

2025-01-13 · 0001615219-25-000007

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2024-12-27 · 9999999995-24-003936

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

Range $1.00 to $6.00 · 6,733,334 shares · Gross proceeds $10,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Selling stockholders only · Use of proceeds Selling stockholders reselling shares; no proceeds to the company · Underwriters C/M Capital Master Fund, LP

2024-12-16 · 0001615219-24-000098

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $335,921

Common Stock · Exchange Nasdaq · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2024-07-25 · 0001615219-24-000066

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $810,973

Common Stock · Exchange Nasdaq · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2024-07-22 · 0001615219-24-000060

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Gross proceeds $536,250

Common Stock · Exchange Nasdaq · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2024-06-17 · 0001615219-24-000052

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

11,163,637 shares

Common Stock · Exchange Nasdaq · Ticker SLRX · Includes pre-funded warrants, Series A-1 warrants, Series A-2 warrants, and placement agent warrants · Selling stockholders only · Use of proceeds Proceeds from warrant exercises · Flags cayman_holding_company, warrants

2023-06-07 · 0001615219-23-000053

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2023-06-06 · 9999999995-23-001659

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2022-08-16 · 9999999995-22-002398

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2022-06-23 · 9999999995-22-001859

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.25 · 9,339,436 shares · Gross proceeds $2,334,859

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Private Placement Warrants to purchase 7,004,578 shares of common stock · Use of proceeds general corporate purposes · Flags warrants, best_efforts · Underwriters Ladenburg Thalmann & Co. Inc.

2022-04-26 · 0001615219-22-000052

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $25,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Underwriters Ladenburg Thalmann & Co. Inc.

2021-07-02 · 0001615219-21-000075

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.12 · 142,711 shares · Gross proceeds $2,164,926

Warrants to purchase common stock · Exchange Nasdaq · Ticker SLRX · Warrants exercisable at $15.17 per share or $0.1198 per warrant, expiring January 20, 2025 · Use of proceeds Gross proceeds to be used for general corporate purposes

2021-07-01 · 0001615219-21-000067

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.37 · 14,614,541 shares · Gross proceeds $20,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Over-allotment 3,000,000 · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters Ladenburg Thalmann

2021-03-05 · 0001193125-21-071701

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Underwriters Ladenburg Thalmann

2021-03-03 · 0001193125-21-067708

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $6,306,000

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Use of proceeds General corporate purposes · Underwriters Ladenburg Thalmann & Co. Inc.

2021-02-05 · 0001193125-21-030930

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2021-02-01 · 9999999995-21-000371

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.20 · 4,461,209 shares · Gross proceeds $5,353,450

Common · Exchange Nasdaq Capital Market · Ticker SLRX · Over-allotment 669,181 · Use of proceeds Proceeds used for working capital and operational expenses · Underwriters Ladenburg Thalmann

2020-07-31 · 0001193125-20-204567

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B4 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Underwriters Ladenburg Thalmann

Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals) is advancing SP-2577 (seclidemstat) in Phase 1/2 clinical trials for advanced solid tumors and Ewing sarcoma, with trial expansion to include additional sarcomas. Preclinical studies explore combinations with immunotherapy and mutations in chromatin-modifying complexes. The company addresses COVID-19 impacts on operations and supply chains while reporting preliminary Q2 2020 financial results showing revenue ranges, operating expenses, and net losses. The filing also details the 2019 merger with Private Salarius and emerging growth company status.

2020-07-29 · 0001193125-20-202678

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $1.15 · 8,347,826 shares · Gross proceeds $9,600,000

Class A and B Units · Exchange Nasdaq Capital Market · Ticker SLRX · Each Class A Unit consists of one share of common stock and a warrant; each Class B Unit consists of one share of Series A Preferred Stock and a warrant · Each warrant entitles the holder to purchase one share of common stock at an exercise price of $1.15 · Use of proceeds to fund operations and general corporate purposes · Flags units, warrants · Underwriters Ladenburg Thalmann

The current filing for Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals) outlines significant risks associated with its clinical development and regulatory approval processes. The company emphasizes the high failure rates in clinical trials, uncertainty in obtaining regulatory approvals, potential adverse side effects, challenges in patient enrollment, and dependence on a single product candidate, Seclidemstat, which is in Phase 1/2 trials. The filing highlights the financial and operational risks tied to its novel epigenetic enzyme therapeutic platform and the potential for delays or failures in product development.

2020-02-10 · 0001193125-20-028933

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2020-02-06 · 9999999995-20-000274

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $3.04 · 2,631,578 shares · Gross proceeds $799,999

Class A, Class B · Exchange Nasdaq Capital Market · Ticker SLRX · Over-allotment 0 · Class A Units consisting of common stock and warrants; Class B Units consisting of Series A Preferred Stock and warrants · Each warrant entitles holder to purchase one share of common stock at unspecified exercise price · Use of proceeds for general corporate purposes · Flags units, warrants · Underwriters Ladenburg Thalmann

Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals) is a biotechnology company focused on developing epigenetic enzyme therapeutics, with its lead candidate Seclidemstat in Phase 1/2 clinical trials for Ewing sarcoma and advanced solid tumors. The company faces significant risks related to clinical trial failures, regulatory approval uncertainties, and reliance on a single product candidate. Its novel technology for modulating gene expression through LSD1 inhibition carries inherent development challenges, including unpredictable costs, safety concerns, and difficulties in patient enrollment. The company has not yet generated revenue and depends heavily on external funding and strategic collaborations.

2020-02-06 · 0001193125-20-025727

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

Exchange NASDAQ

Salarius Pharmaceuticals, Inc. is a biotechnology company focused on developing epigenetic therapies for oncology, with its lead candidate Seclidemstat in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The company highlights its novel LSD1 inhibition technology, potential for accelerated approval, and financial backing from non-dilutive funding sources like CPRIT. The filing emphasizes clinical milestones, market opportunities, and strategic partnerships, while disclosing risks related to unproven technology and regulatory uncertainties.

2020-01-29 · 0001193125-20-017741

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $3.04 · 2,631,578 shares · Gross proceeds $18,400,000

common stock, Series A Preferred Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Class A Units: 1 share of common stock + 1 warrant; Class B Units: 1 share of Series A Preferred Stock (convertible to common stock) + 1 warrant · Warrants to purchase common stock at an unspecified exercise price · Use of proceeds working capital · Flags units, warrants · Underwriters Ladenburg Thalmann

Decoy Therapeutics Inc. (Salarius) faces significant risks in its product development, including challenges in clinical trials, regulatory approvals, and commercialization. The company's reliance on a novel epigenetic enzyme technology introduces uncertainties in development timelines and success. Key risks include clinical trial delays, adverse events, regulatory hurdles, and dependency on a single product candidate, Seclidemstat, in Phase 1/2 trials. The company also highlights difficulties in patient enrollment and potential product liability issues.

2020-01-28 · 0001193125-20-016222

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

Gross proceeds $6,900,000

Class A Units, Class B Units · Exchange Nasdaq Capital Market · Ticker SLRX · Class A Units (common stock + warrants) and Class B Units (Series A Preferred Stock + warrants) · Warrants to purchase common stock at an exercise price not specified in the text · Use of proceeds Proceeds will be used for general corporate purposes · Flags units, warrants · Underwriters Ladenburg Thalmann

Decoy Therapeutics Inc. is advancing novel oncology therapeutics using epigenetic enzyme technology, with its lead candidate Seclidemstat in Phase 1/2 trials for advanced solid tumors. The company faces significant risks in clinical development, regulatory approval, and commercialization. Proceeds from the IPO will fund working capital and general corporate purposes. The filing highlights uncertainties in product development, potential side effects, and dependence on a single product candidate.

2020-01-10 · 0001193125-20-005401

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

Gross proceeds $10,900,000

Common Stock · Exchange NASDAQ · Underwriters Aspire Capital Fund, LLC

The filing details the terms for the distribution of securities, emphasizing global securities held in book-entry form through a depositary. It outlines risks related to indirect ownership, transfer limitations, and the role of underwriters in sales. The plan of distribution includes public offerings, negotiated transactions, and at-the-market offerings, with potential market-making activities by underwriters.

2019-10-28 · 0001193125-19-275560

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-07-18 · 0001193125-19-196567

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-07-15 · 0001193125-19-194018

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-07-12 · 0001193125-19-193221

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B3 in the pre-IPO sequence.

2019-07-01 · 0001193125-19-187275

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

right per share · Exchange NASDAQ

The filing supplements the proxy statement/prospectus regarding Flex Pharma's business combination with Salarius Pharmaceuticals, LLC. It clarifies that Proposal No. 2 (reverse stock split) and Proposal No. 4 (adjournment of the Special Meeting) are 'routine' matters allowing brokers to vote without instructions. It also announces Amendment No. 1 to the merger agreement, extending its term and enabling transferrable rights for stockholders. The Special Meeting was reconvened for July 12, 2019.

2019-06-27 · 0001193125-19-182756

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-26 · 0001193125-19-181982

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-25 · 0001193125-19-180828

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-19 · 0001193125-19-176134

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-17 · 0001193125-19-174479

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-14 · 0001193125-19-173833

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-10 · 0001193125-19-169209

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-10 · 0001193125-19-168794

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-06-06 · 0001193125-19-166777

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-05-31 · 0001193125-19-161853

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-05-28 · 0001193125-19-157798

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows EFFECT in the pre-IPO sequence.

2019-05-22 · 0001193125-19-153943

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 425 and marks the registration effective.

2019-05-17 · 9999999995-19-001144

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-05-17 · 0001193125-19-150053

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2019-05-16 · 0001193125-19-148749

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Flex Pharma, Inc. is seeking shareholder approval for a merger with Salarius Pharmaceutics, LLC. The current filing includes a formal letter from CEO William McVicar urging support for the transaction, which requires majority shareholder approval. The filing emphasizes the importance of voting and provides contact details for proxy assistance.

2019-05-10 · 0001193125-19-144411

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B3 in the pre-IPO sequence.

Flex Pharma, Inc. is seeking shareholder approval for a merger with Salarius Pharmaceuticals, LLC, involving the issuance of common stock, a reverse stock split, and a name change. The filing emphasizes the need for shareholder votes on four proposals, including the merger terms and corporate changes, with the merger contingent on approval.

2019-05-10 · 0001193125-19-144410

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker SLRX · Salarius units converted to Flex Pharma shares · Warrants exercisable for 4,550,233 shares at $0.342 per warrant · Use of proceeds For merger and related transactions · Flags units, warrants

Decoy Therapeutics Inc. (formerly Flex Pharma, Inc.) is undergoing a merger with Salarius Pharmaceuticals, LLC, resulting in a stock exchange where Salarius units convert into Flex Pharma shares. The merger includes a reverse stock split, a name change to Salarius Pharmaceuticals, Inc., and the issuance of Warrants to Flex Pharma shareholders. Shareholders are voting on approvals for the merger, reverse split, and name change, with the combined entity expected to list on Nasdaq under SLRX.

2019-04-30 · 0001193125-19-126517

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-4/A and marks the registration effective.

The filing confirms the effectiveness of Flex Pharma, Inc.'s Form S-4 registration statement related to the merger of its subsidiary Falcon Acquisition Sub, LLC with Salarius Pharmaceuticals, LLC. The merger values Flex Pharma at $10.5 million and Salarius at $36.6 million, with unit conversions to Flex Pharma shares and warrant issuance tied to closing conditions. The document outlines conversion ratios, dividend rights, and warrant terms subject to adjustments based on cash balances and financing.

2019-04-29 · 9999999995-19-000890

S-4/A amended

S-4/A

Pre-IPO filing captured from the SEC submission timeline.

Updates the prior S-4/A filing.

right per share · Exchange NASDAQ · Ticker FLEX · Warrants exercisable for up to ~4,550,233 shares of Flex Pharma common stock with exercise price tied to merger closing date fair market value

Flex Pharma, Inc. is merging with Salarius Pharmaceuticals, LLC, with Salarius surviving as a wholly owned subsidiary. The merger values Flex Pharma at $10.5M and Salarius at $36.6M, with conversion ratios for Salarius units into Flex Pharma shares. A reverse stock split and name change to Salarius Pharmaceuticals, Inc. are planned. Shareholders must approve the transaction, including stock issuance and corporate amendments.

2019-04-18 · 0001193125-19-109509

S-4/A amended

S-4/A

Pre-IPO filing captured from the SEC submission timeline.

Updates the prior S-4 filing.

right per share · Warrants exercisable for shares of Flex Pharma's common stock with exercise price tied to merger closing value · Use of proceeds Merger transaction consideration

Decoy Therapeutics Inc. (Flex Pharma) is merging with Salarius Pharmaceuticals, LLC, with Salarius becoming a wholly owned subsidiary. The merger values Flex Pharma at $10.5M and Salarius at $36.6M, with conversion ratios for Salarius units into Flex Pharma shares. A reverse stock split and name change to Salarius Pharmaceuticals, Inc. are planned, pending shareholder approvals. Warrants and dividends are part of the transaction, affecting ownership percentages.

2019-03-26 · 0001193125-19-085626

S-4 filed

S-4

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Price $0.32 · 76,151,698 shares · Gross proceeds $24,368,543

Common Stock · Exchange NASDAQ · Ticker FLEX · Warrants to purchase shares of common stock with an exercise price based on the closing date's fair market value · Use of proceeds To facilitate the merger with Salarius Pharmaceuticals, LLC, resulting in the exchange of shares · Flags warrants

Flex Pharma, Inc. is merging with Salarius Pharmaceuticals, LLC, with Salarius members receiving Flex Pharma common stock. The merger values Flex at $10.5M and Salarius at $36.6M, subject to adjustments. Shareholders must approve the transaction, including a reverse stock split and name change to Salarius Pharmaceuticals, Inc. Warrants are issued to Flex shareholders, contingent on merger completion.

2019-02-14 · 0001193125-19-038620

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows EFFECT in the pre-IPO sequence.

Flex Pharma, Inc. entered into a merger agreement with Salarius Pharmaceuticals, LLC, under which Salarius will merge into Flex, with Salarius becoming a wholly owned subsidiary. The transaction involves converting Salarius units into Flex common stock, issuing warrants to Flex stockholders, and meeting regulatory and shareholder approval conditions. The merger is structured to qualify as a tax-free exchange under IRS rules.

2019-01-04 · 0001193125-19-002001

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

Flex Pharma, Inc. completed its initial public offering (IPO) with the effectiveness of its S-3 registration statement on April 26, 2016. The company offered 5,400,000 shares of common stock at $16.00 per share, raising $86.4 million. The shares are listed on NASDAQ under the symbol 'FLKS.' The IPO included an underwriter option to purchase an additional 810,000 shares, with underwriters including Jefferies, Piper Jaffray, JMP Securities, Cantor Fitzgerald & Co., and Roth Capital Partners. Flex Pharma is an emerging growth company with reduced reporting requirements and focuses on developing treatments for neuromuscular conditions and consumer products for exercise-associated muscle cramps.

2016-04-26 · 9999999995-16-004331

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $16.00 · 5,400,000 shares · Gross proceeds $86,400,000

Common · Exchange NASDAQ · Ticker FLKS · Over-allotment 810,000 · Underwriters Jefferies, Piper Jaffray, JMP Securities

Flex Pharma, Inc. is conducting its initial public offering (IPO) to raise capital by issuing 5,400,000 shares of common stock at $16.00 per share, totaling $86.4 million. The company, a biotechnology firm focused on developing treatments for nocturnal leg cramps and neuromuscular conditions, plans to list on NASDAQ under the symbol 'FLKS.' The filing highlights its proprietary treatment leveraging TRP receptor activation, with clinical trials in progress. The company is classified as an emerging growth company, subject to reduced reporting requirements.

2015-01-29 · 0001047469-15-000498

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 8-A12B and marks the registration effective.

The current filing marks the effectiveness of Flex Pharma, Inc.'s S-1 registration statement, initiating its IPO process. This follows a prior 8-A12B filing for registering common stock on NASDAQ, indicating the company's transition to a publicly traded entity.

2015-01-28 · 9999999995-15-000225

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows S-1/A and registers the class of securities for exchange listing.

Flex Pharma, Inc. is registering its common stock for listing on The NASDAQ Stock Market LLC, referencing the prospectus included in its prior S-1/A registration statement. The filing confirms the company's intent to raise capital through an initial public offering, with underwriters including Jefferies, Piper Jaffray, and others. The company focuses on developing treatments for neuromuscular conditions, including nocturnal leg cramps, with planned clinical trials.

2015-01-23 · 0001104659-15-004043

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $14.00 · Range $12.00 to $14.00 · 5,307,250 shares · Gross proceeds $74,301,500

Common · Exchange NASDAQ · Ticker FLKS · Over-allotment 692,250 · Use of proceeds general corporate purposes · Underwriters Jefferies, Piper Jaffray, JMP Securities

Flex Pharma, Inc. is conducting an initial public offering (IPO) to raise capital for the development of its proprietary treatments for nocturnal leg cramps and neuromuscular-related spasms. The company's technology targets muscle cramp mechanisms by modulating TRP ion channels in sensory neurons, with planned clinical trials in 2015. The IPO offers 4,615,000 shares at an expected price range of $12.00-$14.00 per share, with underwriters having an option to purchase additional shares. The filing emphasizes the lack of approved treatments for nocturnal leg cramps in the U.S. and highlights the company's focus on both therapeutic and consumer product lines.

2015-01-20 · 0001047469-15-000294

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Common Stock, $0.0001 par value per share · Exchange NASDAQ Global Market · Ticker FLKS · Use of proceeds Use of proceeds includes funding operations and development of proprietary treatments · Underwriters Jefferies, Piper Jaffray, JMP Securities

Flex Pharma, Inc. is a biotechnology company developing proprietary treatments for nocturnal leg cramps and spasms associated with neuromuscular conditions. The company's approach targets alpha-motor neuron hyperexcitability by activating TRP receptors in sensory neurons, with three completed clinical studies showing reduced muscle cramp intensity. They plan to initiate proof-of-concept trials in 2015 and are also developing a consumer product for exercise-associated muscle cramps. The IPO aims to raise $60 million, with underwriters including Jefferies, Piper Jaffray, and others.

2015-01-13 · 0001047469-15-000197

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange NASDAQ Global Market · Ticker FLKS · Underwriters Jefferies, Piper Jaffray, JMP Securities

Flex Pharma, Inc. is a biotechnology company developing proprietary treatments for nocturnal leg cramps and neuromuscular conditions. The company's approach targets alpha-motor neuron hyperexcitability by activating TRP receptors, with three completed clinical studies showing reduced muscle cramps. The S-1 filing outlines plans for an initial public offering (IPO) to fund further clinical trials and commercialization of both pharmaceutical and consumer products. The company aims to address a significant unmet medical need, as no FDA-approved treatments exist for nocturnal leg cramps in the U.S.

2014-12-29 · 0001047469-14-010116

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Flex Pharma, Inc. is a biopharmaceutical company developing proprietary treatments for nocturnal leg cramps and neuromuscular conditions. The company's lead candidate targets muscle cramps by modulating alpha-motor neuron activity through TRP receptor activation. Three Phase 1 studies demonstrated statistical significance in reducing muscle cramps in healthy volunteers. The company plans to initiate proof-of-concept trials for nocturnal leg cramps in 2015 and is also developing a consumer brand for exercise-associated muscle cramps. The filing represents an updated confidential submission for an IPO, with details on clinical development, market opportunity, and underwriters.

2014-12-08 · 0000912057-14-000464

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Flex Pharma, Inc. is a biopharmaceutical company developing proprietary treatments for nocturnal leg cramps and neuromuscular conditions like spasticity and dystonia. Its approach targets TRP ion channels via a formulation containing ginger, cinnamon, and capsicum extracts to reduce alpha-motor neuron hyperexcitability. The company plans clinical trials for its drug candidate and a consumer brand for exercise-associated muscle cramps. This is its initial public offering, with no prior public filings. The offering price range and underwriters (Jefferies, Piper Jaffray, etc.) are disclosed, and the company is classified as an emerging growth company.

2014-10-29 · 0000912057-14-000419

Decoy Therapeutics Inc.

Filing Timeline

17 comparable deals

Recent News